News
Bioiberica is rated good and remains within the A group, representing companies with significant research activity The Spanish chemical-pharmaceutical company, which employs 386 workers, has more than 58 R&D projects currently under development.
Their new project focus on the research and validation of imaging and biochemical biomarkers used to diagnose knee osteoarthritis (OA) prior to the development of symptoms, to identify patients profiles, and to predict disease progression.Biomarkers could be used to measure the efficacy of treatments, thus enabling the National Health System to save money.The Foundation of the National Institu
Last October 2011 Bioibérica, SA was invited to give a talk on poultry nutrition at the annual meeting of the PHILSAN (Philippine Society of Animal Nutritionist).
Faced with the wave of intense cold expected for today and the next few days, experts recommend applying local heat, walking or practice moderate exercise to improve joint mobilityOsteoarthritis affects more than seven million people in Spain. This disease is one of the most common causes of permanent incapacity to work.
Dysgen®, utilizes the innovative liquid DNA beadchip technology to simultaneously detect seven genetic markers associated with hip dysplasia.